Delayed release of the November 10, 2026 edition. News reflects the November 10 research cutoff.Bayer's Sunharbo (asundexian) wins FDA approval for stroke prevention, with bleeding risks shaping patient selection. Beam's risto-cel meets its pivotal sickle cell goal, but a year-end filing could precede detailed public results. Lilly's Foundayo (orforglipron) sleep apnea data, Boehringer and Zealand's survodutide safety result, and the FDA's GLP-1 vision-warning action put benefit and tolerability in focus. Also: Novocure's Optune Mya setback in lung-cancer brain metastases, EMD Serono's pimicotinib approval for tenosynovial giant cell tumor, Compass's COMP360 depression filing, and argenx's deal for Unnatural Products.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →